Haematology

 

Our Team

Professor HANG QUACH – MBBS, SpecCertOC, FRACP, FRCPA, MD
Director of Clinical Haematology + Clinical Haematology Research
Hang

Professor Hang Quach is the head of the Department of Clinical Haematology and is the director of Clinical Haematology Research at St Vincent’s Hospital Melbourne. She is a professor of haematology at the University of Melbourne. Her clinical and translational research focuses on novel therapeutics and their impact on the immunology and the microenvironment in multiple myeloma. As of December 2021, she has secured competitive research funding of more than 13 million AUD towards myeloma research and is highly published in the field of in multiple myeloma. Prof. Quach is also the deputy-chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, where she leads the development and biennial update of the Australian National Treatment Guideline for Multiple Myeloma. She is also the co-chair of the Myeloma Working Group of the Australasian Lymphoma Leukaemia Group (ALLG). She is passionate about improving the standard of care for patients with blood cancers in Australia, not only through clinical care, but also through research and active roles on steering committees of national and international health care groups.
Associate Professor MERROLE COLE-SINCLAIR – MBBS FRACP FRCPA
Director of laboratory Haematology
Merrole

Associate Professor Merrole Cole-Sinclair is a clinical and laboratory haematologist with more than 30 years’ specialist experience. She holds honorary academic positions with the Department of Pathology at the University of Melbourne and the Department of Epidemiology and Preventive Medicine at Monash University. She has received Honorary Life Memberships of the Haematology Society of Australia and New Zealand and the Australian and New Zealand Society of Blood Transfusion and various University and College teaching awards. She is a member of the Council of the Victorian Institute of Forensic Medicine, the National Pathology Accreditation Advisory Council and the Victorian Serious Transfusion Incident Reporting advisory group. She has been a recent Board member of the Royal College of Pathologists of Australasia (RCPA) and Chair of the Australian Committee for Joint College Training in Haematology (Royal Australasian College of Australasia/RCPA). Her clinical interests are in general diagnostic and clinical haematology and transfusion.
Associate Professor MATTHEW KU – MBBS, FRACP, FRCPA, PhD
Matthew

A/Prof Ku is a haematologist with an interest in lymphoproliferative neoplasms. He is currently the Deputy Director of the Haematology Clinical Research Unit, and the Clinical Stream Lead for Aggressive Lymphomas. He is the Lead for the Immune Effector Cell Therapy Steering Committee, with a special interest in immunotherapies. He is the Principal Investigator on multiple international clinical trials that utilise novel therapies in lymphomas, with the aim of improving patient outcomes. A/Prof Ku is the current chairperson for the Membership Relations Working Group of the Australasian Leukaemia and Lymphoma Group, and he is a member of the Australasian Lymphoma Alliance, the Australasian Leukaemia & Lymphoma Group, the Haematology Society of Australia and New Zealand, and the American Society of Hematology. A/Prof Ku is also the current Chair for the St Vincent’s Grand Round Committee, and the Haematology Lead for Cancer Centre Outpatient Clinics. A/Prof Ku's PhD focused on novel pathways in acute myeloid leukaemia, and subsequently his postdoctoral Lymphoma Clinical Fellowship involved managing complex patients on clinical studies. A/Prof Ku has multiple publications in peer-reviewed international journals. He has also presented at many national and international haematology conferences and meetings. Outside of work, A/Prof Ku’s main interests are biking riding with his family, watching sci-fi movies, and sharing a nice meal with his wife.
Dr ROBIN FILSHIE – MBCHB, FRACP, FRCPA, PhD
Robin

Dr Robin Filshie has been a consultant clinical and laboratory Haematologist at St.Vincent’s Hospital Melbourne since 1999. He has a broad expertise across the fields of benign and malignant haematology and is actively involved in clinical trials in a wide range of haematological malignancies at St Vincent’s Public Hospital. He is longstanding member of The Australasian Leukaemia and Lymphoma Group (ALLG) and current member of the ALLG Safety and Data Monitoring Committee. He is also a past chair of the St Vincent’s Hospital Human Research Ethics Committee. He is a keen cyclist and hopes to be able to combine that with some future travel.
Dr MASA LASICA – MBBS, FRACP, FRCPA,
Masa

Dr Masa Lasica is haematologist and clinical researcher at St Vincent’s Hospital, Melbourne where she leads the indolent lymphoma, Chronic Lymphocytic Leukaemia (CLL) and amyloidosis program. Masa graduated from the Australian National University School of Medicine in 2008 and completed her haematology specialist training in Melbourne. In 2017 she was awarded fellowship of the Royal Australasian College of Pathologists and the Royal Australian College of Physicians. She undertook a fellowship at the Transfusion Research Unit, Monash University and Australian Red Cross Blood Service as well as a Trials Fellowship at Eastern Health. Masa’s clinical research focuses on the use of novel agents to improve outcomes in patients with indolent lymphoma, CLL and multiple myeloma. In 2022, she was awarded the RACP Research Entry Scholarship. She is principal and sub-investigator on a number of clinical studies and is a member of the Australasian Leukaemia and Lymphoma Group.
Dr SHUH YING TAN – MBBS, FRACP, FRCPA.
Shuh 

Dr Tan is a consultant haematologist, and the clinical lead for acute myeloid leukaemia, myelodysplastic syndromes, and myeloproliferative disorders. She has a special interest in myeloid disorders, with a focus on the development of novel therapies to improve patient outcomes. She is committed in bridging the inequitable access to treatment, and led the establishment of clinical trials in regional centres and interstate. She also champions the training and mentoring of junior doctors. She is a member of scientific committees in the Australasian Leukaemia and Lymphoma Group, and is also an active member of several other committees including thrombosis, transfusion, and cancer governance.
Associate Professor ALI BAZARGAN – MD, FRACP.
Ali

Associate Professor Ali Bazargan is a senior clinical haematologist at St. Vincent's Hospital. He has a special interest in lymphomas, Langerhans cell histiocytosis and thrombosis. He is the lead clinician for Hodgkin lymphoma and T cell lymphomas and was the former chair of thrombosis committee at St. Vincent's Hospital. He is the principal and sub-investigator in a number of clinical trials. He is an active member of a number of committees and is an international working party member for perioperative management of anticoagulation in International Society of Thrombosis and Haemostasis. He remains a working party member of high-grade lymphoma committee in Australiasian Leukaemia and Lymphoma Group.
Dr SLAVISA NINKOVIC – MBBS, FRACP, FRCPA,
 Slavia  

Dr Ninkovic graduated from the University of Melbourne in 2008, completing advanced training in clinical and laboratory haematology through St. Vincent’s Hospital and the Peter MacCallum Cancer Centre. After an 18 month clinical fellowship at the University College Hospital in London, he returned to St. Vincent’s where he is currently practicing as a clinical and laboratory haematologist and a molecular haematopathologist at the Victorian Cancer Cytogenetics Service. Dr Ninkovic is currently enrolled in a PhD centred on a clinical study assessing a response-adapted approach to treatment of transplant ineligible multiple myeloma patients. Translational research focusing on the immune tumour microenvironment and genomic aberrations in myeloma are integral components of his research activity. He is most excited by advancing developments in the field of diagnostic Haematopathology and how they continually bring us a step closer to delivering personalised treatments for patients with haematological malignancies.
Dr SHIRLENE SIM – MBBS, FRACP, FRCPA,
Shirline

Dr Sim is a dual-trained clinical and laboratory haematologist. After graduating from The University of Melbourne, she went on to complete her basic physician and advanced haematology training at St Vincent’s Hospital, Peter MacCallum Cancer Centre and Royal Melbourne Hospital. She is currently involved in clinical trials and research at St Vincent’s Hospital, and is currently pursuing a higher degree. Dr Sim has a wide interest in both malignant and non-malignant haematology, and is highly dedicated to providing the best possible care to all her patients
Dr KRITIKA CHAIWATANATORN – MBBS, FRACP, FRCPA, PhD
Kritika

Dr Kritika Chaiwatanatorn is a consultant clinical and laboratory haematologist at St Vincent’s hospital. She completed her medical undergraduate degree and postgraduate degree in lymphoma research through the University of Melbourne. She is a fellow of both the Royal Australasian College of Physicians (RACP) as well as the Royal College of Pathologists of Australasia (RCPA). Her interest is in laboratory and general clinical haematology with a specific focus in thrombosis and haemostasis. She is the Chair of St Vincent’s Hospital Venous Thromboembolism (VTE) Steering Committee and actively contributes to St Vincent’s Hospital VTE and anticoagulation related policies. She is the Lead Haematologist of St Vincent’s Thrombosis Clinic and in the Coagulation Department of St Vincent’s Pathology. She has a passion for training the next generation of haematologists.
Dr ANNE DYKES – B.Sc. (Hons), MBChB. MRCP, FRACP, FRCPA
 Anne

Dr Anne Dykes trained in Medicine in Scotland before moving to Melbourne where she specialised in Haematology. She works as a senior Haematologist in the Laboratory and Clinic at St Vincent's Hospital. She is also the Coordinator for Haematology Training in Victoria, Tasmania and NT.

Referral Information

All our Haematologists can be contacted via St Vincent's Switchboard on Ph: (03) 9231 2211

Haematology Clinical Research Centre

Haematology Clinical Research Centre - Current Open to recruitment trials

For more information please contact:
Lisa Demosthenous
Manager of Haematology Clinical Research Centre
lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182

Prof Hang Quach, MBBS (Hons) SpecCertOC FRACP FRCPA MD
Director | Clinical Haematology Service | St Vincent’s Hospital

Director | Clinical Haematology Research | St Vincent’s Hospital
hang.quach@svha.org.au

 

A/Prof Matthew Ku, MBBS SpecCertOC FRACP FRCPA PhD
Deputy Director of Haematology Clinical Research Unit | St Vincent’s Hospital
Haematologist & Lymphoma Lead | St Vincent’s Hospital
matthew.ku@svha.org.au

Multiple Myeloma

Smouldering

ITHACA (SMM)

Phase 3 randomized, open label, multicenter study of Isatuximab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Open to recruitment

Newly Diagnosed

GSK2857916 DREAMM 9 (ND MM)

A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

Open to recruitment

IRiL (ND MM)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma

Open to recruitment

ALLG MM22 / FRAIL-M (ND MM)

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study

Pending to open

ALLG MM23 SeaLAND (ND MM)

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma

Open to recruitment

Janssen 68284528MMY3004 CARTITUDE-5 (ND MM)

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Open to recruitment

Pfizer MAGNETISMM-7 (ND MM)

A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) Versus lenalidomide in patients with Newly Diagnosed Multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation

Pending to Open

Relapsed/

Refractory

AMaRC 19-02 BelaCarD (R/R MM)

A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma.

Open to recruitment

BGB-11417-105 (R/R MM)

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in

Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Open to recruitment

CC-220-MM-002 EXCALIBER (R/R MM)

A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab And Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, And Dexamethasone (Dvd) In Subjects With Relapsed Or Refractory Multiple Myeloma

Pending to open

Celgene CC-92480-MM-001 (R/R MM)

A Phase 1 Multicenter, Open-Label Study To Assess The Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 3 (R/R MM)

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 5 (R/R MM)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK207497 DREAMM 6 (R/R MM)

A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma

Open to recruitment

Nil slots available

GSK2857916 DREAMM 8 (R/R MM)

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

Genentech GO43227 (R/R MM)

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma

Open to recruitment

Janssen 64407564MMY1004 MonumenTAL-2 (R/R MM)

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple

Myeloma

Pending to Open

Janssen 64007957MMY1004 MajesTEC-2

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma

Open to recruitment

Pfizer MAGNETISMM-5 (R/R MM)

An open-label, 3-arm, Multicenter, Randomized Phase 3 Study to Evaluate the efficacy and safety of Elranatamab (pf-06863135) Monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 1 prior line of therapy including Lenalidomide and a proteasome inhibitor

Pending to Open

SANOFI ACT16482 UMBRELLA (R/R MM)

Phase 1-2 UMBRE LLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents

compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Open to recruitment

AMG701 20200446 ProxiMMity-1

A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)

Open to recruitment

Acute  Leukaemia & Myelodysplastic Syndrome

Treatment

Naïve

Newly diagnosed

ALLG AML M23 (HOVON) (TN AML, TN MDS)

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Open to recruitment

ALLG AML M25 (INTERVENE) (ND AML)

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

Open to recruitment

ALLG AMLM24

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Open to recruitment

M15-954 (Verona) (ND MDS)

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Open to recruitment

KER050-MD-201 (ND MDS)

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Open to recruitment

Relapsed Refractory

BGB-11417-103 (R/R Myeloid Malignancies)

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Open to recruitment

Celgene CA059-001 (R/R AML MDS)

A phase 1, open-label, dose finding study of CC-95251 alone and in combination with Antineoplastic agents in subjects with Acute myeloid leukemia and Myelodysplastic syndromes

Pending to Open

Myelofibrosis

Relapsed Refractory

KER050-MF-301 (R/R MF)

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis

Open to recruitment

Chronic Lymphocytic Leukaemia

Treatment Naïve

BGB3111_304 (TN CLL)

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma

Open to recruitment

Treatment Naïve & Relapsed Refractory

BGB-11417-101 (TN, R/R CLL)

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Open to recruitment

PCYC-1145-LT (R/R CLL)

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Need to be from an eligible Parent study

Chronic Myeloid Leukaemia

Treatment Naive

ASCEND-CML study CML13 (ND CML)

An ALLG single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia

Open to recruitment

Waldenström Macroglobulinemia

Treatment Naïve &

Relapsed Refractory

Ascentage APG2575WU101 MAPLE-1 (TN WM, R/R WM)

A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenström Macroglobulinemia

Open to recruitment

Lymphomas

Treatment Naïve

ALLG NHL30 PETReA (TN FL)

Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

Open to recruitment

BGB-3111-306 Mangrove (TN MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Open to recruitment

COALITION (TN DLBCL)

A Multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL)

Open to recruitment

MOR208C310 FRONTmind (TN DLBCL)

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)

Open to recruitment

Relapsed Refractory

ALLG NHL33 – WAMM (R/R MCL)

An ALLG Window study of Acalabrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma

Open to recruitment

Ascentage APG-2575-001 (Mono) (R/R CLL, WM, DLBCL, AML, NHL, MCL,RRMM)

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with hematologic malignancies

Open to recruitment

BGB-11417-101 (R/R) B-cell NHL

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Open to recruitment

BGB-A317-210 TIRHOL (R/R cHL)

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Open to recruitment

Dizal DZ2019J0005 – JACKPOT (PTCL)

A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerabilty, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)

Open to recruitment

Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic leukaemia

Open to recruitment

GENMAB GCT3013-01 (R/R DLBCL and FL)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Open to recruitment

GILEAD Magrolimab (R/R NHL)

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

Open to recruitment

IGM Biosciences IGM-2323-001 (R/R NHL)

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Open to recruitment

MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Open to recruitment

PCYC-1143-CA (MCL)

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

Open to recruitment

Roche CO43116 (R/R DLBCL)

A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or without Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Open to recruitment

Roche GO41944 (R/R DLBCL)

A Phase III, Open-Label, Multicentre, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination with Gemcitabine plus Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Open to recruitment

Bleeding Disorders

DIAAMOND (Aplastic Anaemia)

Section A: Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia - The DIAAMOND Ava-FIRST Trial

Section B: Avatrombopag iN Relapsed or Refractory severe aplastic anaemia as EXtra Therapy – The DIAAMOND Ava-NEXT Trial

Open to recruitment

Registries / Other

Myeloma 1000 Registry

The Myeloma 1000 Project

Open to recruitment

MRDR Registry

Myeloma & Related Diseases Registry

Open to recruitment

NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)

Open to recruitment

C-SMART

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial

Open to recruitment

Covid-19 vaccination study (WILLOW)

A prospective study to investigate responses to COVID-19 vaccination in patients with Chronic Lymphocytic Leukemia (CLL) or Waldenstrom Macroglobulinemia

Open to recruitment

COVID 19 Study

A Multi-Centre National study of COVID-19 infection in Cancer patients

Open to recruitment

LaRDR (Lymphoma and Related Disease Registry)

Lymphoma and Related Diseases Registry (LaRDR)

Open to recruitment

Health Pathways

HealthPathways Melbourne is an online portal designed to be used by general practice at the point of care to guide best practice assessment, management and referral of common clinical conditions.

 

Please Note:
This is a public outpatient service. All patients need to be referred to us by a GP. Please see your GP if you believe you would benefit from a referral to this clinic. Many doctors have private consulting suites as well as working in the public hospital system. This is entirely separate from St Vincent’s and our staff do not have any information about the private consulting practices of doctors.

 

Mandatory field(s) marked with *